Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,956,109 papers from all fields of science
Search
Sign In
Create Free Account
AT 101
Known as:
AT-101
, AT101 cpd
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Gossypol
gossypol acetic acid
l-gossypol
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Glioblastoma multiforme hücre kültürlerinde (U-87 MG ve T98G) VEGF sentezinin (-/-) gossipol (AT-101) ile inhibisyonu
B. Çakar
2013
Corpus ID: 149576117
2010
2010
Phase Ib dose-escalation study of MetMAb, a monovalent antagonist antibody to the receptor MET, in combination with bevacizumab in patients with locally advanced or metastatic solid tumors.
R. Moss
,
J. Bothos
,
+7 authors
Premal H. Patel
2010
Corpus ID: 73092038
e13050 Background: Crosstalk between the Met and vascular endothelial growth factor (VEGF) pathways may be important during…
Expand
2010
2010
Synergistic cytotoxic/apoptotic effects of AT-101, a phytochemical with BH3-mimetic property, in combination with paclitaxel in human breast cancer cells.
Ş. Karaca
,
U. Muslu
,
+5 authors
R. Uslu
2010
Corpus ID: 74128146
e21082 Background: Breast cancer is the most common malignancy diagnosed among women. Gossypol is a natural polyphenolic compound…
Expand
2008
2008
Phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer after prior platinum containing first line chemotherapy
R. Heist
,
J. Molina
,
+6 authors
T. Lynch
2008
Corpus ID: 78351621
19004 Background: Antiapoptotic members of the Bcl-2 protein family are expressed in the tumor tissue of the majority of patients…
Expand
2007
2007
Preclinical studies of orally active, pan Bcl-2 small molecule inhibitor AT-101 in small cell lung cancer.
Guangfeng Wang
,
P. Min
,
+4 authors
Dajun Yang
2007
Corpus ID: 85867952
A51 Small cell lung cancer (SCLC) is an aggressive form of lung cancer accounting for approximately 18% of all cases of lung…
Expand
2007
2007
Synergistic effect of AT-101, an orally active pan Bcl-2 family proteins inhibitor in combination with dual-Raf/MEK and VEGFR kinase inhibitor Sorafenib (Nexavar)
Xiongwen Zhang
,
Guangfeng Wang
,
+4 authors
Dajun Yang
2007
Corpus ID: 74083147
AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 1452 The Raf /MEK kinase cascade are pivotal regulators of cellular…
Expand
2007
2007
Improvement of chemoradiation response in head and neck cancer by (-)Gossypol (AT-101), a small molecule inhibitor of Bcl-XL/Bcl-2
M. W. Brekel
,
M. Lafleur
,
M. Verheij
2007
Corpus ID: 79309356
2005
2005
Targeting Antiapoptotic Bcl-2 Family Members with AT-101 in Pre-Clinical Models of Aggressive Lymphoma in Combination with Cyclophosphamide (C) and Rituximab (R) Produces a Marked Improvement in…
L. Paoluzzi
,
M. Gonen
,
+5 authors
O. O'Connor
2005
Corpus ID: 79276035
Abstract Over-expression of anti-apoptotic members of the Bcl-2 family, including Bcl-2 and Bcl-XL, have been observed in more…
Expand